C
rohn's disease (CD) is a chronic relapsing inflammatory condition that primarily affects young individuals, often leading to significant impairment of quality of life. At present, potent medical therapies, including biologics and immunosuppressives, are often reserved as last-resort treatments for patients refractory to conventional management. Due to a lack of useful prognostic markers, current disease management remains largely clinically guided. However, symptoms usually correlate poorly with disease activity and better prognostic markers are needed.
In our recently published study, we found that combination immunosuppressive therapy with infliximab and azathioprine led to significantly higher mucosal healing rates compared with conventional management (CM) in patients with newly diagnosed CD, despite comparable clinical steroid-free remission rates after 2 years of treatment. 1 To date, the clinical benefit of achieving complete mucosal healing has not yet been demonstrated in a prospective study. Recent data from a Norwegian popu-lation-based cohort, before the era of biologics, suggested that mucosal healing is predictive of reduced disease activity and decreased need for active treatment and surgery. 2 In the current study, we prospectively followed a cohort of newly diagnosed Crohn's patients for 2 years after ileocolonoscopy, focusing on the differences in clinical outcomes of patients who achieved complete mucosal healing compared with those who had persistent endoscopic activity. We hypothesized that patients achieving complete mucosal healing had superior long-term clinical outcomes.
Methods
This was a prospective, 2-year follow-up of a previously published study in a cohort of CD patients. 1 In summary, 133 newly diagnosed and treatment-naïve CD patients were randomized at 18 centers to receive either combined immunosuppressive treatment (CIS) with azathioprine (2.5 mg/kg) and 3 infusions of infliximab 5 mg/kg or CM with initial corticosteroid therapy. In the CIS group, patients with a relapse were given repeated infliximab infusions as needed. In the CM group, azathioprine was given on flare-up after a second course of corticosteroids or when steroids could not be tapered according to a fixed scheme. Infliximab was given only after failure of 3 months of azathioprine. The initial study started in May 2001 when the first patient was randomized, and continued through January 2004 when the last patient had reached year 2. 1 Eight of the 18 centers participated in an endoscopic substudy. All 49 patients (26 CIS, 23 CM) at these centers who were treated per protocol underwent ileocolonoscopy at year 2. Endoscopic activity was scored using the Simple Endoscopic Score (SES-CD). 3 Complete mucosal healing was defined as a SES-CD of 0, meaning no signs of active inflammation in any colonic segment or in the terminal ileum.
This study reports on the extended follow-up of these 49 patients through years 3 and 4 (the 2 years following endoscopic evaluation). All patients followed strict treatment guidelines until the last patient had reached year 2 and the initial trial had formally ended. Thereafter, patients continued with the same treatment or were treated according to currently accepted guidelines at the discretion of the investigator. After January 2006, patients in need of repeated infliximab infusions were switched from episodic ("on demand") to maintenance infliximab treatment every 8 weeks according to revised guidelines. 4 Detailed clinical data including treatment were collected for all patients.
All patients were seen for outpatient clinic visits on a routine basis every 3 months until the last patient in the study had reached year 2. At each of these 3 monthly visits, a Crohn's Disease Activity Index (CDAI) was calculated. Median follow-up for these measurements in the current study was 19.2 months. After this period, patients were evaluated clinically using the Harvey Bradshaw Index and physical examination. In addition, investigators completed follow-up questionnaires for each patient at the end of year 3 and year 4. The questionnaire was comprised of clinical parameters regarding disease status (overall disease status, flares, fistulas, endoscopy, x-rays), disease-related medications, adverse events, comorbidities, and disease-related hospitalizations. Overall disease status was summarized as follows: "clinical remission" was defined as a symptom-free state throughout the entire 2-year follow-up period, "mildly active," "moderately active," or "severely active," defined per average CDAI at different outpatient clinic visits and/or as determined by the principal investigators. The main endpoint of this study was stable remission and no use of corticosteroids during the entire 2-year follow-up period. For remission, the classical CDAI criterion (Ͻ150) was used or a Harvey Bradshaw Index Ͻ3. A flare was defined as any change in the disease course that required an unscheduled visit or admission to the hospital and or a change in medication. Patients needing repeated infliximab infusion because of a flare were not considered in remission. In contrast, patients who were switched from an on-demand schedule to maintenance infliximab every 8 weeks were counted separately. Therefore, an additional endpoint, "in remission off steroids and no antiϪtumor necrosis factor (TNF) therapy" was used to split up remissions with or without infliximab.
Informed consent was obtained from all patients to extend the initial study. This follow-up was approved by the central and local institutional review boards at each participating center.
Statistical Analysis
Data for clinical remission were combined for years 3 and 4 (the 2 years following the endoscopic evaluation). Mucosal healing was used as a binary variable (healing or no healing) as was done in other studies. 1,2 A Fisher's exact 2-sided test was used to compare the mucosal healing group with the nonmucosal healing group. Statistical Program for the Social Sciences 17.0 (SPSS Inc, Chicago IL) was used for statistical analysis. An ␣ level of 5% was considered as threshold for significance. In addition, multiple logistic regression analysis was performed with all variables and showed a trend toward significance in univariate analysis (P Ͻ .1) included in the model.
Results

Data Collection
The initial trial included 129 evaluable patients of a total of 133 patients randomized in 18 centers. Eight centers agreed to participate in an endoscopic substudy. All 49 patients from these 8 centers underwent an ileocolonoscopy 2 years after enrollment in the initial trial. These patients had similar baseline characteristics compared with the entire main study sample. At the time of follow-up analysis, year-4 data were available in 46 (94%) of 49 patients (25 CIS; 21 CM). Three patients were lost to follow-up. Complete mucosal healing (SES-CD ϭ 0) was observed in 24 patients (52%; 18 CIS; 6 CM) and endoscopic activity (SES-CD Ͼ0) was observed in 22 patients (48%; 7 CIS; 15 CM). The 2-year SES-CD did not correlate with the CDAI or with any other clinical parameters at inclusion in the initial study. 1
Remission Rates
Several potential predictive factors both at diagnosis and at year 2 were studied. Age, location of CD, smoking history, CDAI, hematocrit, and C-reactive protein levels at diagnosis were not significantly correlated with prognosis. Remission status (or CDAI), C-reactive protein, hematocrit, and previous infliximab use at year 2 did not correlate with clinical outcomes either (Tables 1  and 2 ). Although a higher proportion of patients initially treated with combined immunosuppression treatment were in remission than of those treated with CM, multiple logistics regression analysis revealed that endoscopic healing was the only significant factor.
Stable, steroid-free remission was observed through years 3 and 4 in 17 of 24 (70.8%) patients achieving complete mucosal healing (SES-CD of 0) at year 2, compared with only 6 (27.3%) of 22 patients with endoscopic activity (SES-CD 1-9) (P ϭ .036; odds ratio ϭ 4.352; 95% confidence interval, 1.10Ϫ17.220). Steroid-free remission without anti-TNF therapy was observed in 15 of 24 (62.5%) patients in the SES-CD ϭ 0 group, but in only 4 of 22 (18.2%) patients in the SES-CD ϭ 1 to 9 group (P ϭ .032; odds ratio ϭ 4.883; 95% confidence interval, 1.144Ϫ20.844) (Figure 1 
Adverse Events, Comorbidities, and Hospitalizations
One patient (4.2%) with complete mucosal healing reported a persistent perianal fistula, and 5 of 22 (22.7%) patients with a SES-CD 1 to 9 reported a new (n ϭ 2) or persistent actively (n ϭ 3) draining perianal fistula during follow up (P ϭ .089).
A total of 23 flares in 14 patients were observed during the study. Six flares occurred in 4 of the 24 (16.7%) patients with mucosal healing compared to 17 flares in 10 of the 22 (45.5%) patients in the group with endoscopic activity. The number of flares per patient is shown in Figure 2 .
No major resective bowel surgery for CD was performed in either group. Minor Crohn's surgery, including incision and drainage of abscesses, was performed in 1 patient in the SES-CD 0 group and in 3 patients in the SES-CD Ͼ0 group. One patient in the mucosal healing group was hospitalized for a flare of CD, although there were no hospitalizations in the endoscopic activity group. No significant differences in the number of other minor and serious adverse events were noted between the 2 groups (Table 3) .
Medication Use Beyond Year 2
At the beginning of this follow-up study, there were no significant differences in medication use between the CM and the CIS group. All but 3 patients remained on immunosuppressives throughout the study. These 3 patients were in the mucosal healing group (SES-CD 0) and maintained stable clinical remission despite discontinuation of all medical therapies. No patients in the endoscopic activity group (SES-CD 1Ϫ9) maintained stable clinical remission without medication. During the study anti-TNF therapy was used in 8 (33%; 7 infliximab, 1 adalimumab) of the 24 patients in the SES-CD 0 compared to 14 (64%; 12 infliximab, 2 adalimumab) of 22 patients in the SES-CD 1 to 9 group. All medication use, both maintenance and add-on medication is summarized in Table 4 . 
Discussion
This is the first prospective study examining the clinical predictive value of mucosal healing in patients with CD in the era of the biologics and immunosuppressants. This study is an extended follow-up study of our earlier reported study comparing combined immunosuppressive treatment to conventional management (The Step Up Versus Top Down Study) in treatment-naïve early CD patients. 1 We hypothesized that patients achieving mucosal healing at the end of 2 years would have better outcomes in the subsequent 2 years (years 3Ϫ4). We observed a clear statistical difference in remission rates for the patients with complete mucosal healing as assessed by endoscopy 2 years after initiation of their first therapy for CD. In addition, only 1 of 24 patients with mucosal healing had a persistently active draining fistula. In contrast to 5 of 22 patients with endoscopic activity that developed a new fistula or had persistent fistula activity. Finally, more flares were seen in the group with endoscopic activity during the 2-year follow-up. No difference was observed in the number of hospitalizations or major surgery in the 2 groups. This is probably due to the limited sample size and/or duration of follow-up. None of the other markers analyzed both at diagnosis and at year 2 was predictive for clinical remission in the next 2 years. Mucosal healing was a predictive marker irrespective of the CDAI. CDAI at year 2 did not correlate with mucosal healing.
Two decades ago, Rutgeerts et al reported on the value of an endoscopic score to predict recurrent CD after a "curative resection." 5, 6 Similarly, there is now a growing body of evidence that endoscopic appearance may also be of predictive value in "established disease." Frøslie et al reported that mucosal healing at 1 year predicted a decreased need for steroid therapy and less anal fistula activity in a Norwegian population-based Inflammatory Bowel Disease cohort. 2 This study is a cohort study of a population treated with corticosteroids and mesalamine, before immunosupressants and biologic therapy were widely used in Norway and therefore probably reflects the natural history of the disease.
With the advent of immunosuppressants, and especially anti-TNF therapy, mucosal healing rates increased considerably. 7, 8 Emerging evidence suggests that these therapies will not only reduce disease activity but also long-term complication rates. Following the A Crohn's Disease Clinical Study Evaluating Infliximab in a New Long Term Treatment Regimen (ACCENT-1) trial, patients with complete or near-complete endoscopic healing at week 54 were in remission for a median of 19 to 20 weeks following the final endoscopy, compared to only 4 weeks in patients without signs of healing. 9 In the same trial, patients with absence of ulcers had fewer operations and hospitalizations than patients without mucosal healing. 10 A limitation of our current study is that medical treatment was no longer standardized after termination of the initial study. However, median follow-up of our patients in the formal trial beyond their 2-year endoscopy was 19.2 months. During this period, treatments were comparable among both groups with almost uniform maintenance therapy with azathioprine. Better outcomes in the mucosal healing group cannot be explained by the difference in medication use because use of infliximab was lower in the mucosal healing group.
When we stratified patients with and without healing based upon their initial disease management (CM or CIS), we found no differences in clinical outcomes (data not shown), confirming that achieving mucosal healing is the sole determining predicting factor and not the treatment.
All Crohn's medication could be stopped without flare of the disease for 2 years in 3 patients in the mucosal healing group. These results are in agreement with recent findings of an early rheumatoid arthritis study in which 19% of patients treated with a combination of infliximab and methotrexate from the start were in remission and could stop all medication at 5 years' follow-up. 11 Mounting evidence on the efficacy and relative safety of biologics and immunosupressants both as monotherapy and in combination are challenging the current paradigm of "step-up" therapy guided by clinical success or failure rather than by predictive markers. 12 Recent data from the Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease (SONIC) trial have confirmed the superiority of combined immunosuppression achieving mucosal healing in early CD. 13 Although current use of biologics has changed to maintenance therapy, our data, systematically and prospectively collected in a well-defined cohort of treatment-naïve Crohn's patients, support the strategy of aggressive induction therapy, including biologic therapy (so-called "top down") in early CD, with possibly subsequent stepdown therapy when complete mucosal healing is reached.
Future research should continue to explore the value of mucosal healing. Stool markers, including calprotectin and lactoferrin, have been suggested as reliable noninvasive substitutes for endoscopy. 14 Others have suggested that transmural healing might be a superior endpoint, although correlations between mucosal and transmural healing have not yet been studied. In the future, novel imaging methods, such as computed tomography or magnetic resonance imaging enterography/enteroclysis may prove to be superior. Clearly there is a compelling need to move beyond conventional management in Crohn's therapy.
This prospective clinical study provides evidence that complete mucosal healing can lead to significantly higher steroid-free remission rates through 2 years in patients with CD. Given that we have previously shown that mucosal healing rates in the CIS group were higher, these data further support that a top-down approach in early CD can alter its disease course.
